Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI scans 3000 liver cancer patients to pick best therapy

NCT ID NCT07368530

Knowledge-focused Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study analyzed medical images and data from 3000 patients with advanced liver cancer that cannot be removed by surgery. Researchers used an AI technique called radiomics to see if they could identify which patients would respond better to one of two standard treatments: TACE (a procedure that blocks the tumor's blood supply) or HAIC (chemotherapy delivered directly to the liver). The goal is to develop a tool that helps doctors personalize treatment decisions, but because this is a retrospective study looking at past data, it cannot prove that the AI model will work for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the best liver cancer treatment for each patient, improving outcomes without a one-size-fits-all approach.
What could go wrong
This is a retrospective study, meaning it looks back at old data, so it cannot prove cause and effect. The AI model may not work as well in new patients or other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,000 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with unresectable HCC who TACE or HAIC

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients diagnosed with hepatocellular carcinoma (HCC) based on clinical or pathological criteria; 2. Barcelona Clinic Liver Cancer (BCLC) stage B or C, assessed as unresectable by surgical evaluation; 3. Received either TACE or HAIC as the sole interventional treatment modality throughout the treatment course (no crossover between the two modalities allowed); 4. Liver function classified as Child-Pugh Class A or B, or achieved this standard after medical treatment; 5. Performance status (PS) score of 0 or 1. Exclusion Criteria: 1. Patients with an unclear diagnosis or those with concurrent other malignant tumors; 2. Liver function classified as Child-Pugh Class C or worse, which cannot be improved after hepatoprotective treatment; 3. Patients with severe infections, such as respiratory, biliary tract, or abdominal infections; 4. Patients with severe underlying diseases, particularly immune-related disorders. 5. Patients with severely incomplete or missing baseline or outcome data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCLC stage B hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCLC stage B hepatocellular carcinoma BCLC stage C hepatocellular carcinoma Unresectable hepatocellular carcinoma (HCC)

Contacts and locations

Locations

  • The First Affiiated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.